Cargando…
Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring Plateletpheresis
Immune thrombocytopenic purpura (ITP) causes thrombocytopenia through the autoimmune destruction of platelets. Corticosteroids remain the first line of therapy, and traditionally splenectomy has been the second. While the availability of thrombopoietin receptor agonists (TPO-RAs) has expanded treatm...
Autores principales: | Zimmerman, Jacquelyn, Norsworthy, Kelly J., Brodsky, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080471/ https://www.ncbi.nlm.nih.gov/pubmed/27812394 http://dx.doi.org/10.1155/2016/5403612 |
Ejemplares similares
-
A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists
por: Khan, Meaghan, et al.
Publicado: (2010) -
Therapeutic platelet reduction: Use in postsplenectomy thrombocytosis
por: Negi, Gita, et al.
Publicado: (2015) -
Severe case of refractory immune thrombocytopenic purpura requiring splenectomy after the COVID-19 vaccine
por: Koilpillai, Sarina, et al.
Publicado: (2022) -
Reoperation of Lower Extremity Microsurgical Reconstruction When Facing Postsplenectomy Thrombocytosis
por: Song, Ping, et al.
Publicado: (2019) -
Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)